Figure 2.

Mechanisms of blocking CD47-SIRPα axis therapies in OC. First, blocking the CD47-SIRPα axis could clear tumor cells by restoring macrophage phagocytosis and promoting tumor-associated macrophages to differentiate toward the M1 subtype (upper right). Second, anti-CD47/SIRPα-blocking mAbs or SIRPα-fusion proteins could clear tumor cells through classical Fc-dependent mechanisms, including NK cell-mediated ADCC (lower left) and macrophage-mediated ADCP (upper right). Third, blocking the CD47-SIRPα axis might indirectly stimulate adaptive immunity by promoting DCs uptake by tumor cells and cross-presentation to CD8⁺ T cells (upper left). Fourth, blocking the CD47-SIRPα axis could directly clear tumor cells by caspase-independent apoptosis (lower right). Abbreviations: ADCC, antibody-dependent cytotoxicity; ADCP, antibody-dependent phagocytosis; DC, dendritic cells; M1, M1-like macrophages; M2, M2-like macrophages; NK cells, natural killer cells; OC, ovarian cancer.